

FDA clears Scpio Labs digital cell morphology platform

June 17, 2022—[Scpio Labs](#) received FDA 510(k) clearance for its X100HT hematology digital cell morphology platform with peripheral blood smear review.

“We’re excited to expand our suite of fully digital AI-powered diagnostic platforms to accelerate PBS analysis, improve consistency of results, and reduce review time,” Erez Naaman, CTO and cofounder of Scpio Labs, said in a press statement. “At Scpio, we are determined to usher in the digital revolution to laboratory medicine. Our devices offer complete remote capabilities for real-time diagnosis and treatment decisions, allowing experts to review, collaborate, and consult from anywhere, and at any time, using our AI-powered applications.”

The X100HT holds 30 slides and processes up to 40 samples per hour. The system also features full-field imaging at 100x resolution and supports remote review capabilities.